Olanzapin Hexal (Olanzapine)

Olanzapine, the active ingredient in Olanzapin Hexal, is an atypical antipsychotic presented as a tablet for oral use. It is prescribed for the management of schizophrenia and bipolar disorder in adults.

GNH USA supplies Olanzapin Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olanzapin Hexal is an atypical antipsychotic that modulates neurotransmitter activity in several psychiatric conditions. - Schizophrenia: helps reduce hallucinations, delusions and thought disorder. - Bipolar I disorder (manic episodes): assists with mood stabilization and reduction of manic symptoms. - Bipolar II disorder (depressive episodes) : may improve depressive symptoms when used as part of a broader treatment plan.

Olanzapin Hexal may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Weight gain: increased appetite and caloric intake. - Sedation: drowsiness or feeling of being slowed down. - Dry mouth: reduced salivation. - Constipation: slowed gastrointestinal motility. - Orthostatic hypotension: light‑headedness on standing. - Elevated prolactin: menstrual changes or galactorrhoea.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability. - Tardive dyskinesia: involuntary, repetitive movements, especially of the face. - Severe hyperglycaemia: marked increase in blood glucose levels. - Agranulocytosis: dangerously low white‑blood cell count. - Seizures: new‑onset convulsive episodes. - Hepatotoxicity: elevated liver enzymes or liver injury.

When prescribing Olanzapin Hexal, clinicians should evaluate patient history and monitor for specific safety concerns. - Cardiovascular assessment: check for pre‑existing heart disease or arrhythmias. - Metabolic monitoring: regularly measure weight, fasting glucose and lipid profile. - Psychiatric review: assess for worsening depression or suicidal ideation. - Pregnancy & lactation: weigh benefits against potential risks; use only if clearly needed. - Drug‑interaction check: review concomitant medications for additive CNS depression. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Olanzapin Hexal can interact with several medicines that affect its metabolism or amplify central nervous system effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase olanzapine plasma levels. - Strong CYP1A2 inducers (e.g., rifampicin, carbamazepine): may reduce olanzapine effectiveness. - CNS depressants (benzodiazepines, opioids): heightened sedation and respiratory depression risk.

Moderate Interactions (Monitor Closely): - Antihistamines and other antipsychotics: additive sedation. - Antidiabetic drugs: potential alteration of glucose control. - Anticholinergic agents: increased risk of constipation and urinary retention.